| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | B2BKR; B2BRA; B2R; BDKRB2; BK2 receptor; BK2R; BKR2; BR B2; BRB2; Kinin B2 |
| Entrez GeneID | 624 |
| WB Predicted band size | Calculated MW: 44 kDa; Observed MW: 80-100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human BDKRB2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于BDKRB2抗体的3篇参考文献示例(注：以下为模拟内容，具体文献需根据实际数据库检索验证)：
---
1. **文献名称**: *Role of BDKRB2 in inflammatory angiogenesis: Insights from antibody blockade studies*
**作者**: Smith A, et al.
**摘要**: 本研究通过使用BDKRB2特异性抗体，探讨了缓激肽受体B2在炎症诱导的血管生成中的作用。实验显示，抗体阻断BDKRB2后显著抑制了内皮细胞迁移和血管新生，提示该受体在病理血管形成中的关键地位。
2. **文献名称**: *BDKRB2 antibody-based targeting in sepsis-induced vascular dysfunction*
**作者**: Chen L, et al.
**摘要**: 研究利用BDKRB2中和抗体，评估其在脓毒症模型中对血管通透性的调控。结果显示，抗体治疗降低了血浆缓激肽水平，并改善了内皮屏障功能，为脓毒症治疗提供了潜在策略。
3. **文献名称**: *Genetic and pharmacological inhibition of BDKRB2 in hypertension*
**作者**: Gupta R, et al.
**摘要**: 通过结合BDKRB2抗体与基因敲除模型，本文揭示了该受体在高血压相关血管收缩中的作用。抗体干预显著降低了血管平滑肌细胞的钙信号响应，提示其作为降压靶点的潜力。
---
建议通过PubMed或Google Scholar检索关键词“BDKRB2 antibody”或“B2 bradykinin receptor antibody”获取真实文献。部分研究可能聚焦于抗体在疾病机制、药物开发或诊断中的应用。
The BDKRB2 (bradykinin receptor B2) antibody is a tool used to detect and study the bradykinin B2 receptor, a G protein-coupled receptor (GPCR) encoded by the BDKRB2 gene. This receptor binds bradykinin, a peptide involved in inflammatory and pain pathways, vasodilation, and vascular permeability. BDKRB2 is constitutively expressed in healthy tissues and plays a role in mediating physiological responses such as blood pressure regulation, edema, and nociception. Antibodies targeting BDKRB2 are essential for research into cardiovascular diseases, inflammatory disorders, and cancer, where aberrant bradykinin signaling is implicated.
These antibodies are typically validated for applications like Western blotting, immunohistochemistry, and flow cytometry to assess receptor localization, expression levels, or activation states. Specificity is critical, as BDKRB2 shares structural similarities with the bradykinin B1 receptor (BDKRB1), which is upregulated during tissue injury. High-quality BDKRB2 antibodies help distinguish between these receptors in experimental models.
Studies using BDKRB2 antibodies have elucidated its role in pathologies, including hypertension, sepsis, and angiogenesis in tumors. They also aid in evaluating therapeutic agents targeting bradykinin pathways. Commercial BDKRB2 antibodies are often raised in rabbits or mice, with validation across human, rat, and mouse samples. Proper controls are necessary to confirm specificity, as off-target binding can complicate data interpretation. Overall, BDKRB2 antibodies are vital for advancing research on inflammatory and vascular mechanisms.
×
